Magyar
Toggle navigation
Tudóstér
Magyar
Tudóstér
Keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Böngészés
Saját polc tartalma
(
0
)
Korábbi keresések
Összesen 1 találat.
#/oldal:
12
36
60
120
Rövid
Hosszú
MARC
Részletezés:
Rendezés:
Szerző növekvő
Szerző csökkenő
Cím növekvő
Cím csökkenő
Dátum növekvő
Dátum csökkenő
1.
001-es BibID:
BIBFORM003767
Első szerző:
Torp-Pedersen, Christian
Cím:
Cardiovascular responses to weight management and sibutramine in high-risk subjects : an analysis from the SCOUT trial / Torp-Pedersen, C., Caterson, I., Coutinho, W., Finer, N., Van Gaal, L., Maggioni, A., Sharma, A., Brisco, W., Deaton, R., Shepherd, G., James, P., Czuriga, I. and SCOUT Investigators
Dátum:
2007
Megjegyzések:
The Sibutramine Cardiovascular OUTcomes (SCOUT) trial is a randomized, double-blind comparison of sibutramine vs. placebo, in addition to standard care for weight management, in overweight/obese subjects with an increased risk of cardiovascular disease. The study had an initial single-blind, 6-week lead-in period with sibutramine plus weight management. We report the cardiovascular responses and weight loss during this period. METHODS AND RESULTS: A total of 10,742 subjects received treatment in the lead-in period; 97% had cardiovascular disease, 88% hypertension and 84% type 2 diabetes. Body weight decreased (median 2.2 kg [5th, 95th percentile changes -6.2, 0.5]); waist circumference was reduced by 2.0 cm (men: -8.5, 2.9; women: -9.0, 3.0), systolic blood pressure fell by 3.0 mmHg (-23.5, 12.5) and diastolic by 1.0 mmHg (-13.5, 10.0). Pulse rate increased by 1.5 b.p.m. (-11.0, 13.5). All changes were statistically significant (P < 0.001). Two consecutive increases in blood pressure or pulse rate of >10 mmHg/b.p.m. were observed in 4.7 and 3.5% of subjects, respectively. Fifteen subjects (0.1%) died; 10 deaths were attributed to a cardiovascular cause, equivalent to 1.2 and 0.8 deaths per 100 years of exposure, respectively. CONCLUSION: Six-week treatment with sibutramine appears to be efficacious, tolerable and safe in this high-risk population for whom sibutramine is usually contraindicated
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
Aged
analysis
Appetite Depressants
blood
Blood Pressure
Body Weight
Cyclobutanes
Diabetic Angiopathies
Double-Blind Method
drug therapy
Female
Humans
Hypertension
Male
methods
Middle Aged
mortality
Obesity
Reproducibility of Results
Risk
Risk Assessment
Risk Factors
therapeutic use
Weight Loss
Megjelenés:
European Heart Journal. - 28 : 23 (2007), p. 2915-2923. -
További szerzők:
Caterson, Ian
Coutinho, Walmir
Finer, Nick
Gaal, Luc, Van
Maggioni, Aldo
Sharma, Arya
Brisco, Wygenia
Deaton, Roger
Shepherd, Gillian
James, Philip
Czuriga István (1948-2018) (kardiológus)
SCOUT Investigators
Internet cím:
elektronikus változat
DOI
Borító:
Saját polcon:
Rekordok letöltése
1
Corvina könyvtári katalógus v8.2.27
© 2023
Monguz kft.
Minden jog fenntartva.